Roger G. Pertwee
School of Medical Sciences
Institute of Medical Sciences
University of Aberdeen
Foresterhill
Scotland
Name/email consistency: high
- Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation. Pertwee, R.G. Proc. Natl. Acad. Sci. U.S.A. (2012)
- Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Pertwee, R.G. Curr. Med. Chem. (2010)
- Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Pertwee, R.G. Br. J. Pharmacol. (2009)
- The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Pertwee, R.G. Br. J. Pharmacol. (2008)
- Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Pertwee, R.G. Addict. Biol (2008)
- GPR55: a new member of the cannabinoid receptor clan? Pertwee, R.G. Br. J. Pharmacol. (2007)
- Cannabinoids and multiple sclerosis. Pertwee, R.G. Mol. Neurobiol. (2007)
- Cannabinoid pharmacology: the first 66 years. Pertwee, R.G. Br. J. Pharmacol. (2006)
- The pharmacology of cannabinoid receptors and their ligands: an overview. Pertwee, R.G. Int. J. Obes. (Lond) (2006)
- Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Pertwee, R.G. Life Sci. (2005)
- Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. Pertwee, R.G., Thomas, A., Stevenson, L.A., Maor, Y., Mechoulam, R. Neuropharmacology (2005)
- The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. Pertwee, R.G. AAPS. J (2005)
- Pharmacological actions of cannabinoids. Pertwee, R.G. Handb. Exp. Pharmacol (2005)